Overview

Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors

Status:
Terminated
Trial end date:
2018-01-30
Target enrollment:
Participant gender:
Summary
This study will determine the safety and maximum tolerated dose of ONO-7579 in patients with advanced solid tumors, and evaluate efficacy of ONO-7579 in patients with advanced solid tumors harboring NTRK gene fusions.
Phase:
Phase 1
Details
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Treatments:
ONO-7579